Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kala Pharmaceuticals Inc (KALA)
NASDAQ:KALA
RESEARCH TOOLSreports
Holding KALA?
Track your performance easily
KALA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.21 - $10.97
Previous Close$5.68
Volume21.43K
Average Volume (3M)234.98K
Market Cap
$26.17M
Enterprise Value$8.77M
Total Cash (Recent Filing)$54.20M
Total Debt (Recent Filing)$36.80M
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
Nov 07, 2024EPS Estimate
-$2.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.95
Shares Outstanding4,607,569
10 Day Avg. Volume13,502
30 Day Avg. Volume234,979
Standard Deviation0.85
R-Squared0.02
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)1.94
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.24
Forecast
1Y Price Target
$15.00Price Target Upside171.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Kala Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementProgress in the company's pivotal clinical trials is expected to generate significant data, potentially catalyzing advancements in persistent corneal epithelial defect treatment.
Financial StabilityThe company maintains a robust financial position with substantial cash reserves, ensuring operational funding for multiple upcoming years.
Therapeutic DevelopmentThe company's lead asset, a pioneering treatment for persistent corneal epithelial defects, is in the advanced stages of clinical trials, indicating a strong potential for medical breakthroughs.
Bears Say
Clinical Trial DelaysThe Company now plans to report topline results from the CHASE trial in H2:24 from Q2:24.
Drug Development RisksRisks include, but are not limited to: (1) failure of KPI-012 in clinical trials; (2) failure of KPI-012 to obtain regulatory approval.
Financial PerformanceNet loss totaled $8.7M in 3Q23.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KALA FAQ
What was Kala Pharmaceuticals Inc’s price range in the past 12 months?
Kala Pharmaceuticals Inc lowest stock price was $4.21 and its highest was $10.97 in the past 12 months.
What is Kala Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Kala Pharmaceuticals Inc’s upcoming earnings report date?
Kala Pharmaceuticals Inc’s upcoming earnings report date is Nov 07, 2024 which is in 44 days.
How were Kala Pharmaceuticals Inc’s earnings last quarter?
Kala Pharmaceuticals Inc released its earnings results on Aug 06, 2024. The company reported -$3.16 earnings per share for the quarter, beating the consensus estimate of -$4.405 by $1.245.
Is Kala Pharmaceuticals Inc overvalued?
According to Wall Street analysts Kala Pharmaceuticals Inc’s price is currently Undervalued.
Does Kala Pharmaceuticals Inc pay dividends?
Kala Pharmaceuticals Inc does not currently pay dividends.
What is Kala Pharmaceuticals Inc’s EPS estimate?
Kala Pharmaceuticals Inc’s EPS estimate is -$2.43.
How many shares outstanding does Kala Pharmaceuticals Inc have?
Kala Pharmaceuticals Inc has 4,607,569 shares outstanding.
What happened to Kala Pharmaceuticals Inc’s price movement after its last earnings report?
Kala Pharmaceuticals Inc reported an EPS of -$3.16 in its last earnings report, beating expectations of -$4.405. Following the earnings report the stock price went up 4.034%.
Which hedge fund is a major shareholder of Kala Pharmaceuticals Inc?
Among the largest hedge funds holding Kala Pharmaceuticals Inc’s share is Baker Bros Advisors LP. It holds Kala Pharmaceuticals Inc’s shares valued at 6M.
---
Kala Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (171.74% Upside)
$15.00 (171.74% Upside)
Hedge Fund Trend
Increased
By 624.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 11.7%
Last 30 Days ▲ 11.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.08%
12-Months-Change
Fundamentals
Return on Equity
-248.11%
Trailing 12-Months
Asset Growth
-7.36%
Trailing 12-Months
Company Description
Kala Pharmaceuticals Inc
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Watertown, MA.
---
KALA Stock 12 Month Forecast
Average Price Target
$15.00
▲(171.74% Upside)
Technical Analysis
Best Analysts Covering KALA
1 Year
1 Year Success Rate
0/15 ratings generated profit
1 Year Average Return
-72.30%
assigned a buy rating last month
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -72.30% per trade.
---